Sunday, April 22, 2018
I had the opportunity to stop by the offices of ChromaDex (CDXC) last week in LA. It was a beautiful day in LA and I was in a good mood. From the Company's side, in attendance were Robert Fried,...
Tailwinds' Take: this study reached easily reached the primary endpoint of demonstrating that Niagen increases NAD+ levels. Importantly, the cardiovascular data shows that it has great potential in helping people with high blood pressure. Further studies are definitely warranted...
Shares of Chromadex are not cheap. When you look at this company relative to sales, the $200+ million market cap sticks out like a green thumb. For a supplement company its valued more like a biotech; you're really betting...
IRVINE, Calif., March 08, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corporation (NASDAQ:CDXC), a science-based, integrated nutraceutical company devoted to improving the way people age, announced today fourth quarter and full year 2017 financial results. Results of operations for the three months ended Dec. 30, 2017 For the...
Thanks to a recent article in Time Magazine, Nicotinamide Riboside and NAD replenishment are getting a lot of attention. Because I have been taking NR for 18 months, and have been following the science closely, I will attempt to explain...
Tailwinds' Take: with nearly 140 trials underway involving Niagen, CDXC has more than its share of catalysts coming in the near future. These two new trials for for Alzheimers and CHF...two areas that have had very positive mouse trials...
One of our top picks, Chromadex shares have been under pressure over the last few months. The shares hit a high of around $7 in November, but worked their way lower, trading as low as $4.50 last week. This...
Tailwinds' Take: Revenue exceeded Company and Wall Street forecasts. Singapore launch coming in Q1. Well positioned for a huge 2018. IRVINE, Calif., Feb. 12, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corporation (NASDAQ:CDXC), a science-based, integrated nutraceutical company devoted to pioneering technologies that improve the way...
Tailwinds' Take: yet another positive study result for what will surely become a blockbuster supplement. CDXC stock has traded well off its highs. Great time to look at it.  The supplement nicotinamide riboside (NR) – a form of vitamin B3...
Tailwinds' Take: while not unexpected, a very important win for CDXC, which takes away the biggest potential concern for the Company.  IRVINE, Calif., Jan. 22, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age,...
Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address